Adjuvant Activity of Free Bordetella Pertussis Filamentous Haemagglutinin Delivered by Mucosal Routes

Scandinavian Journal of Immunology

Volumn 58, Issue 5, 2003, Pages 503-510

  Poulain Godefroy, O ^a   Menozzi, F D ^b   Alonso, S ^b   Vendeville, C ^a   Capron, A ^a   Locht, C ^b   Riveau, G ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HEMAGGLUTININ; HEMOCYANIN; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RECOMBINANT ANTIGEN; RECOMBINANT ENZYME; TRANSFORMING GROWTH FACTOR BETA; TRIPLE VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN BINDING; ANTIGEN DETECTION; ANTIGEN SPECIFICITY; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; CROSS LINKING; CROSS REACTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; IMMUNOGENICITY; MOUSE; MUCOSA; NONHUMAN; PERTUSSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VACCINE PRODUCTION;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, CD80; FEMALE; GENES, MHC CLASS II; GLUTATHIONE TRANSFERASE; HEMAGGLUTININS; HEMOCYANIN; MICE; SCHISTOSOMA MANSONI; TRANSFORMING GROWTH FACTOR BETA; VIRULENCE FACTORS, BORDETELLA;

EID: 0242658675     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01336.x     Document Type: Article

References (36)

1. Walker R. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994;12:387-400.
2. Snider DP, Marshall JS, Perdue MH, Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1994;153:647-57.
3. Tamura S, Shoji Y, Hasiguchi K, Aizawa C, Kurata T. Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine 1994;12:1238-40.
4. Yamamoto M, McGhee JR, Hagiwara Y, Otake S, Kiyono H. Genetically manipulated bacterial toxin as a new generation mucosal adjuvant. Scand J Immunol 2001;53:211-7.
5. Ginkel VFW, Jackson RJ, Yuki Y, McGhee JR. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol, 2000; 165:4778-82.
6. Russel MW, Martin MH, Wu HY, Hollingshead SK, Moldoveanu Z, Mestecky J. Strategies of immunization against mucosal infections. Vaccine 2001;19:S122-7.
7. Mestecky J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol 1987;7:265-76.
8. Ivanoff N, Phillips N, Schacht AM, Heydari C, Capron A, Riveau G. Mucosal vaccination against schistosomiasis using liposome-associated Sm28kDa glutathione S-transferase. Vaccine 1996;14: 1123-31.
9. Poulain-Godefroy O, Mielcarek N, Ivanoff N et al. Enhancement of immunogenicity by intranasal antigen delivery using liposomes bearing the Bordetella pertussis filamentous hemagglutinin. Infect Immun 1998;66:1764-7.
10. Hannah JH, Menozzi FD, Renauld G, Locht C, Brennan MJ. Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin-binding domain on FHA. Infect Immun 1994;62:5010-9.
11. Tuomanen E, Towbin H, Rosenfelder G et al. Receptor analogs and monoclonal antibodies that inhibit adherence of Bordetella pertussis to human ciliated respiratory epithelial cells. J Exp Med 1988;168:267-77.
12. Ishibashi Y, Claus S, Relman DA. Bordetella pertussis filamentous hemagglutinin interacts with a leucocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18). J Exp Med 1994;180:1225-33.
13. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkanen K, Wright SD. Recognition of a bacterial adhesin by an integrin: Macrophage CR3 (aMb2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 1990;61:1375-82.
14. Balloul JM, Grzych JM, Pierce RJ, Capron A. A purified 28,000 dalton protein from Schistosoma mansoni adult worms protects rats and mice against experimental schistosomiasis. J Immunol 1987;138:3448-53.
15. Trottein F, Kieny MP, Verwaerde C et al. Molecular cloning and tissue distribution of a 26 kDa glutathione S -transferase from Schistosoma mansoni. Mol Biochem Parasitol 1990;41:35-44.
16. Menozzi FD, Gantiez C, Locht C. Interaction of Bordetella pertussis filamentous hemagglutinin with heparin. FEMS Microbiol Lett 1991;78:59-64.
17. Antoine R, Locht C. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin. Infect Immun 1990;58:1518-26.
18. Alonso S, Pethe K, Mielcarek N, Raze D, Locht C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesln redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect Immun 2001;69:6038-43.
19. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
20. Nedrud JG, Liang X, Hague N, Lamm ME. Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol 1987;139:3484-92.
21. Baras B, Benoit MA, Poulain-Godefroy O et al. Vaccine properties of antigens entrapped in microparticules produced by spray-drying technique and using various polyester polymers. Vaccine 2000;18:1495-505.
22. Cherry JD. Historical review of pertussis and the classical vaccine. J Infect Dis 1996;174 (Suppl. 3):S259-63.
23. Kimura A, Mountzouros KT, Relman DA, Falkow S, Cowell JL. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect Immun 1990;58:7-16.
24. Locht C, Bertin P, Menozzi FD, Renauld G. The filamentous haemagglutinin, a multifaced adhesin produced by virulent Bordetella spp. Mol Microbiol 1993;9:653-60.
25. Prasad SM, Yin Y, Rodzinski E, Tuomanen EI, Masure HR. Identification of a carbohydrate recognition domain in filamentous hemagglutinin from Bordetella pertussis. Infect Immun 1993;61: 2780-5.
26. Menozzi FD, Mutombo R, Renauld G et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect Immun 1994;62:769-78.
27. Shahin RD, Amsbaugh DF, Leef MF. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect Immun 1992;60:1482-88.
28. Cahill ES, O'Hagan DT, Ilium L, Barnard A, Mills KHG, Redhead K. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles. Vaccine 1995;13:455-62.
29. Plotkin SA, Cadoz M. The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 1997;16:508-17.
30. Wilson AD, Clarke CJ, Stokes CR. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol 1990;31:443-51.
31. Medina E, Talay SR, Chhatwal GS, Guzman CA. Fibronectin-binding protein I of Streptococcus pyogenes is a promising adjuvant for antigens delivered by mucosal route. Eur J Immunol 1998;28:1069-77.
32. McGuirk P, Mills KHG. Direct anti-inflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur J Immunol 2000;30:415-22.
33. McGuirk P, McCann C, Mills HG. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002;195:221-31.
34. Ishibashi Y, Nichikawa A. Bordetella penussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin. Microb Pathog 2002;33:115-25.
35. Thomas MG, Ashworth LA, Miller E, Lambert HP. Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine. J Infect Dis 1989;160:838-45.
36. Leininger E, Bowen S, Renauld-Mongenie G et al. Immunodominant domains present on the Bordetella pertussis component filamentous haemagglutinin. J Infect Dis 1997;175:1423-31.